
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Korea's Lotte Biologics signs tripartite MoU to develop antibody-drug conjugates toolbox

June 18, 2025 | News

Aims to enhance ADC capabilities through collaborative innovation with specialised partners



Lotte Biologics, Axcelead Drug Discovery Partners, Inc., and Kanaph Therapeutics Inc. have signed a tripartite Memorandum of Understanding (MoU) to build an ADC Toolbox for the development of antibody-drug conjugates (ADCs).

Through this agreement, the three companies will collaborate on the joint research and development of linker and payload technologies, which are key components in the development of next-generation ADC cancer therapies.

Axcelead Drug Discovery Partners, Inc., a world-class drug discovery platform Contract Research Organization (CRO) by inheriting the drug discovery platform from Takeda Pharmaceutical Company in Japan, plans to leverage a compound library comprising more than 1.2 million compounds and more than 1,000 legacy projects, to generate novel payload candidates not yet applied to ADCs.

Kanaph Therapeutics Inc. will focus on developing an innovative platform that addresses the limitations of existing linker and payload technologies in ADC development.

The linker and payload technologies developed through this collaboration will be transferred to South Korea-based Lotte Biologics, which will utilise them to further enhance the competitiveness of its ADC platform, including SoluFlex Link.

Lotte Biologics plans to offer an ADC Toolbox service, enabling clients to select and apply a variety of technologies tailored to their needs. This service is expected to reinforce the company’s one-stop platform encompassing the entire ADC modality process, from research and development to GMP manufacturing.